J.P. Morgan Raises PT on Thermo Fisher Scientific (TMO) Keeps an Overweight Rating

​Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the Best Forever Stocks to Invest In Now. On October 9, J.P. Morgan analyst Casey Woodring raised the firm’s price target on Thermo Fisher Scientific Inc. (NYSE:TMO) from $600 to $650, while keeping an Overweight rating on the stock.

​The rating comes ahead of the company’s fiscal third-quarter results, which are expected on October 22, 2025. The analyst noted that they see the life sciences tool companies taking a more conservative stance in their 2026 outlook as they wait for pending evidence for order improvement. The firm has lowered 2026 numbers for many companies in the group, but remains Overweight on Thermo Fisher Scientific Inc. (NYSE:TMO).

​Thermo Fisher Scientific Inc. (NYSE:TMO) raised its full-year guidance during the FQ2 2025 earnings call. It now expects revenue to be in the range of $43.6 billion to $44.2 billion, and adjusted EPS in the range of $22.22 to $22.84 per share.

​Thermo Fisher Scientific Inc. (NYSE:TMO) accelerates life sciences research and improves patient health by providing instruments, reagents, and consumables for biological research.

While we acknowledge the potential of TMO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.